Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents

被引:9
作者
Reddy, Paavani S. [1 ]
Cai, Stephanie W. [2 ]
Barrera, Leonardo [3 ]
King, Kathryn [3 ,4 ]
Badawy, Sherif M. [4 ,5 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Med Educ, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA
[3] Ann & Robert H Lurie Childrens Hosp Chicago, Mary Ann & J Milburn Smith Child Hlth Res Outreac, 225 E Chicago Ave,Box N 30, Chicago, IL 60611 USA
[4] Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol & Stem Cell Transplant, Chicago, IL 60611 USA
[5] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
Sickle cell; adherence; compliance; hydroxyurea; hydroxycarbamide; chronic pain; health care utilization; AYA; adolescents and young adults; haemoglobinopathy; QUALITY-OF-LIFE; MEDICATION ADHERENCE; PEDIATRIC-PATIENTS; CARE UTILIZATION; VASOOCCLUSIVE CRISES; HOSPITALIZATIONS; BARRIERS; ANEMIA; PREDICTORS; MORTALITY;
D O I
10.1080/07853890.2022.2044509
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Sickle cell disease (SCD) results in severe complications, such as anaemia and pain episodes. Hydroxyurea (HU) is efficacious in SCD, yet adherence remains low. Objective To assess the relationship of HU adherence to health care utilization and patients' characteristics. Methods This is a 5-year retrospective chart review. Patients' demographics and medical history were collected from the electronic medical record (EMR). HU adherence was evaluated using foetal haemoglobin "HbF%", mean corpuscular volume "MCV", and absolute neutrophil count "ANC". Age groups included children (<12 years), adolescents (12-17 years), and young adults (>= 18 years). Results A total of 113 SCD patients on HU were included (median age 14 years, IQR 10-20; 50% female; 88% HbSS). Young adults had significantly higher HU adherence compared to adolescents and children, including higher median HbF% (24.2 vs. 12.4 vs. 8.6, p = .003), MCV (fl) (106.4 vs. 96.2 vs. 95.4, p = .01) and lower ANC (10(3)/ml) (3.25 vs. 4.9 vs. 4.2, p = .01), respectively. Patients with chronic pain had lower HU adherence (HbF% 15.3 vs. 10.7, p = .04; ANC 3.6 vs. 6.3, p = .002; MCV 102.3 vs. 93.1, p = .1). Patients with higher HbF or MCV and lower ANC had significantly less frequent emergency room visits (r(s)=-0.26, p = .01; r(s)=-0.23, p = .01; r(s)=0.24, p = .01) and hospitalizations (r(s)=-0.27, p = .01; r(s)=-0.31, p = .01; r(s)=0.21, p = .02) as well as shorter length of stays (r(s)=-0.27, p = .0045; r(s)=-.34, p = 0.004; r(s)=0.23, p = .02), respectively. Similar trends in HU adherence and health care utilization were seen in subgroup analysis of only HbSS patients. There was no significant association of HU adherence to patients' sex, socio-economic status, distance from hospital, and HU duration. Conclusions Young adults with SCD had significantly higher HU adherence compared to children and adolescents. Patients with lower HU adherence and/or chronic pain had increased health care utilization. Future studies examining barriers to adherence and evaluating interventions to optimize HU adherence in SCD are warranted. KEY MESSAGES Young adults with SCD had significantly higher HU adherence, as reflected in their laboratory markers, compared to children and adolescents. Patients with higher HU adherence and/or those without chronic pain had lower or less frequent health care utilization. No significant association of HU adherence to patients' sex, socio-economic status and distance from hospital.
引用
收藏
页码:683 / 693
页数:11
相关论文
共 62 条
  • [31] Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease
    Haywood, Carlton, Jr.
    Beach, Mary Catherine
    Bediako, Shawn
    Carroll, C. Patrick
    Lattimer, Lakshmi
    Jarrett, Dasheema
    Lanzkron, Sophie
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (01) : 85 - 87
  • [32] Hydroxyurea for Children with Sickle Cell Disease
    Heeney, Matthew M.
    Ware, Russell E.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (01) : 199 - +
  • [33] Frequent and prolonged hospitalizations: A risk factor for early mortality in sickle cell disease patients
    Houston-Yu, P
    Rana, SR
    Beyer, B
    Castro, O
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2003, 72 (03) : 201 - 203
  • [34] Predictors of Health-Related Quality of Life over Time Among Adolescents and Young Adults with Sickle Cell Disease
    Jackson, Jamie L.
    Lemanek, Kathleen L.
    Clough-Paabo, Emily
    Rhodes, Melissa
    [J]. JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS, 2014, 21 (04) : 313 - 319
  • [35] Sickle cell disease
    Kato, Gregory J.
    Piel, Frederic B.
    Reid, Clarice D.
    Gaston, Marilyn H.
    Ohene-Frempong, Kwaku
    Krishnamurti, Lakshmanan
    Smith, Wally R.
    Panepinto, Julie A.
    Weatherall, David J.
    Costa, Fernando F.
    Vichinsky, Elliott P.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2018, 4
  • [36] Systematic and Meta-Analytic Review: Medication Adherence Among Pediatric Patients With Sickle Cell Disease
    Loiselle, Kristin
    Lee, Jennifer L.
    Szulczewski, Lauren
    Drake, Sarah
    Crosby, Lori E.
    Pai, Ahna L. H.
    [J]. JOURNAL OF PEDIATRIC PSYCHOLOGY, 2016, 41 (04) : 406 - 418
  • [37] Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease
    Lubeck, Deborah
    Agodoa, Irene
    Bhakta, Nickhill
    Danese, Mark
    Pappu, Kartik
    Howard, Robin
    Gleeson, Michelle
    Halperin, Marc
    Lanzkron, Sophie
    [J]. JAMA NETWORK OPEN, 2019, 2 (11) : E1915374
  • [38] Barriers to Treatment Adherence for Pediatric Patients With Sickle Cell Disease and Their Families
    Modi, Avani C.
    Crosby, Lori E.
    Guilfoyle, Shanna M.
    Lemanek, Kathleen L.
    Witherspoon, Dawn
    Mitchell, Monica J.
    [J]. CHILDRENS HEALTH CARE, 2009, 38 (02) : 107 - 122
  • [39] National Heart Lung and Blood Institute, 2012, WHAT IS SICKL CELL A
  • [40] Hydroxyurea (hydroxycarbamide) for sickle cell disease
    Nevitt, Sarah J.
    Jones, Ashley P.
    Howard, Jo
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (04):